Verboon C, Harbo T, Cornblath DR, et al. - Among patients with mild Guillain-Barré syndrome (GBS), this investigation was carried out to compare the disease course between patients treated with intravenous immunoglobulin (IVIg) or supportive care only. Participants were selected from the prospective observational International GBS Outcome Study. Those patients were included who were able to walk independently at study entry (mild GBS), managed with one IVIg course or supportive care. It was found that IVIg treatment was not related to lower GBS disability scores at 4 weeks. The overall disease course in mild GBS patients was not improved by one course of IVIg. The certainty of this inference is limited by confounding factors, selection bias and wide confidence limits. Following one year, presence of residual symptoms was frequently evident, suggesting the requirement for better treatments in mild GBS.